Q97927165

Summary

Q97927165 is a committee group motion^[1].

Key Facts

• Q97927165 authored Cristina Husmark Pehrsson^[2].
• Q97927165 authored Carl-Axel Johansson^[3].
• Q97927165 authored Anne Marie Brodén^[4].
• Q97927165 authored Magdalena Andersson^[5].
• Q97927165 authored Lena Adelsohn Liljeroth^[6].
• Q97927165 authored Stefan Hagfeldt^[7].
• Q97927165's instance of is recorded as committee group motion^[8].
• Q97927165's part of the series is recorded as motions of the 2003-2004 legislative session of the Riksdag^[9].
• Q97927165's language of work or name is recorded as Swedish^[10].
• Q97927165 was released on +2003-12-04T00:00:00Z^[11].
• Q97927165's main subject is medication^[12].
• Q97927165's work available at URL is recorded as http://data.riksdagen.se/dokument/GR02So8^[13].
• Q97927165's work available at URL is recorded as http://data.riksdagen.se/dokumentstatus/GR02So8^[14].
• Q97927165's applies to jurisdiction is recorded as Sweden^[15].
• Q97927165's legal citation of this text is recorded as Mot. 2003/04:So8^[16].
• Q97927165's title is recorded as med anledning av prop. 2003/04:32 Genomförande av EG-direktivet om kliniska prövningar av humanläkemedel^[17].
• Q97927165's has immediate cause is recorded as Q98138704^[18].
• Q97927165's cites work is recorded as Q98138704^[19].
• Q97927165's maintained by WikiProject is recorded as Project Riksdagen's documents^[20].
• Q97927165's copyright status is recorded as public domain^[21].
• Q97927165's legislative committee is recorded as Committee on Health and Welfare^[22].

Body

Definition and Type

Q97927165's instance of is recorded as committee group motion^[8].